Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 6/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27530374 | 1.00 | HPGD (0.49) | HPGDTSHRNPSR1ALDH1A1NPC1 | |
| SCHEMBL1625646 | 0.94 | — | — | |
| SCHEMBL7016675 | 0.94 | — | — | |
| SCHEMBL6444441 | 0.94 | — | — | |
| Acetic Acid SCHEMBL28449373 | 0.88 | HPGD (0.47) | HPGDTSHRNPSR1ALDH1A1NPC1 | |
| SCHEMBL28601788 | 0.87 | — | — | |
| SCHEMBL4914347 | 0.87 | — | — | |
| SCHEMBL28589967 | 0.87 | — | — | |
| Propionic Acid SCHEMBL28449795 | 0.83 | HPGD (0.43) | HPGDTSHRNPSR1ALDH1A1NPC1 | |
| SCHEMBL5046503 | 0.83 | HPGD (0.44) | HPGDTSHRNPSR1ALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1121118-A4 | FORMAMIDES AS THERAPEUTIC AGENTS | GLAXO GROUP LTD (GB) | 2002-09-11 | — | — | EP | claimed |
| EP-1121118-A1 | FORMAMIDES AS THERAPEUTIC AGENTS | GLAXO GROUP LIMITED (GB) | 2001-08-08 | — | — | EP | claimed |
| US-6172064-B1 | METALLOPROTEASE INHIBITOR; ANTIARTHRITIC AGENTS, ANTIDIABETIC AGENTS; ANTITUMOR AGENTS | GLAXO WELLCOME INC. | 2001-01-09 | — | — | US | claimed |
| WO-2000012083-A1 | FORMAMIDES AS THERAPEUTIC AGENTS | GLAXO GROUP LIMITED (GB) | 2000-03-09 | — | — | WO | claimed |
| WO-2026098644-A1 | TARGETED PROTEIN DEGRADATION AGENT, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 北京森妙生物科技有限公司 | 2026-05-15 | — | — | WO | disclosed |
| WO-2026090509-A1 | SPIRO HETEROCYCLIC CDK2 INHIBITORS | ARCHITECT THERAPEUTICS, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| EP-4633734-A1 | COMPOUNDS, COMPOSITIONS, AND MEZHODS OF TREATING DISORDERS ASSOCIATED WITH PROTEIN MISFOLDING | Wavebreak Therapeutics, LLC (US) | 2025-10-22 | — | — | EP | disclosed |
| US-20250197406-A1 | INDAZOLES AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) INHIBITORS AND METHODS FOR USING SAME | 1ST Biotherapeutics, Inc. (KR) | 2025-06-19 | — | — | US | disclosed |
| CN-119896745-A | Glycoside-containing peptide linkers for antibody-drug conjugates | R.P.谢勒技术有限责任公司 | 2025-04-29 | — | — | CN | disclosed |
| CN-119896746-A | Glycoside-containing peptide linkers for antibody-drug conjugates | R.P.谢勒技术有限责任公司 | 2025-04-29 | — | — | CN | disclosed |
| CN-113874046-B | Glycoside-containing peptide linkers for antibody-drug conjugates | R.P.谢勒技术有限责任公司 | 2025-02-28 | — | — | CN | disclosed |
| CN-113727979-B | Novel catecholamine prodrugs for the treatment of parkinson's disease | H.隆德贝克有限公司 | 2024-09-20 | — | — | CN | disclosed |
| US-20090131458-A1 | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-05-21 | — | — | US | disclosed |
| WO-2008101867-A1 | PURINE DERIVATIVES AS IMMUNOMODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-08-28 | — | — | WO | disclosed |
| CN-1989104-A | Cyclic amide derivatives, their preparation and their use as antithrombotic agents | TAKEDA PHARMACEUTICAL (JP) | 2007-06-27 | — | — | CN | disclosed |
| EP-1121118-A4 | FORMAMIDES AS THERAPEUTIC AGENTS | GLAXO GROUP LTD (GB) | 2002-09-11 | — | — | EP | disclosed |
| EP-1121118-A1 | FORMAMIDES AS THERAPEUTIC AGENTS | GLAXO GROUP LIMITED (GB) | 2001-08-08 | — | — | EP | disclosed |
| US-6172064-B1 | METALLOPROTEASE INHIBITOR; ANTIARTHRITIC AGENTS, ANTIDIABETIC AGENTS; ANTITUMOR AGENTS | GLAXO WELLCOME INC. | 2001-01-09 | — | — | US | disclosed |
| WO-2000012083-A1 | FORMAMIDES AS THERAPEUTIC AGENTS | GLAXO GROUP LIMITED (GB) | 2000-03-09 | — | — | WO | disclosed |
| EP-0342541-A2 | Retroviral protease inhibitors | ABBOTT LABORATORIES (US) | 1989-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131458-A1 | Compounds | LTC4S, LTB4R2, LTB4R | HPGD 281/4885TSHR 4286/4885NPSR1 917/4885 |
| US-20250197406-A1 | INDAZOLES AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) INHIBITORS AND METHODS FOR USING SAME | IP6K1, HIPK1, IP6K3 | HPGD 540/4885TSHR 4740/4885NPSR1 4677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.